Vomaris Innovations, a developer of wound care technologies, has appointed Michael Nagel as the new president and chief executive officer (CEO).

Previously, Nagel worked as chief commercial officer (COO) at Neomend and was responsible for the commercial launch of a PMA device, Progel, a pleural air leak sealant in the US and Europe.

He served at Incisive Surgical as Sales and Marketing vice president where he launched a new, absorbable skin closure technology, INSORB in the US and Europe.

Nagel also servedVascular Solutions (VASC) as Sales and Marketing co-founder and vice president.

At VASC, he led to the launch of a novel, biological vascular closure device into the interventional marketplace.

Vomaris chairman Paul Foster said with expertise ranging from diagnostics to cardiovascular devices, Nagel’s proven leadership skills in commercializing biological sealants, hemostats and biomaterials will drive the regenerative technology at Vomaris forward.

"In addition, he brings unparalleled expertise in launching new technology into the medical marketplace that will help Vomaris expand its reach and become a global company," Foster added.

Vomaris Innovations president and CEO Michael Nagel said driven by the increasing number of patients suffering from full-thickness wounds, there is a need to provide an advanced technology that will help expedite wound healing while reducing the associated pain and scarring.

"Vomaris is changing how wounds are managed, which will enhance the quality of patient care worldwide," Nagel said.